Loading...

Celgene

DB:CG3
Snowflake Description

Solid track record and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CG3
DB
$66B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
CG3 Share Price and Events
7 Day Returns
-0.5%
DB:CG3
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
15.6%
DB:CG3
-10.6%
DE Biotechs
-6.2%
DE Market
CG3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Celgene (CG3) -0.5% 7.1% 9.5% 15.6% -14.7% 63.4%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • CG3 outperformed the Biotechs industry which returned -10.6% over the past year.
  • CG3 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
CG3
Industry
5yr Volatility vs Market

Value

 Is Celgene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Celgene to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Celgene.

DB:CG3 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 21 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CG3
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (30.78%))
1.536
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.54
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.536 * 5.96%)
9.38%

Discounted Cash Flow Calculation for DB:CG3 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Celgene is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:CG3 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.38%)
2019 7,760.40 Analyst x5 7,094.85
2020 9,828.60 Analyst x5 8,215.05
2021 10,718.50 Analyst x4 8,190.52
2022 10,988.25 Analyst x4 7,676.54
2023 10,942.75 Analyst x4 6,989.12
2024 10,918.43 Est @ -0.22% 6,375.52
2025 10,908.91 Est @ -0.09% 5,823.66
2026 10,909.72 Est @ 0.01% 5,324.60
2027 10,917.74 Est @ 0.07% 4,871.53
2028 10,930.83 Est @ 0.12% 4,459.08
Present value of next 10 years cash flows $65,020.48
DB:CG3 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $10,930.83 × (1 + 0.23%) ÷ (9.38% – 0.23%)
$119,699.43
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $119,699.43 ÷ (1 + 9.38%)10
$48,829.72
DB:CG3 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $65,020.48 + $48,829.72
$113,850.20
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $113,850.20 / 702.45
$162.08
DB:CG3 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:CG3 represents 0.88865x of NasdaqGS:CELG
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88865x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 162.08 x 0.88865
€144.03
Value per share (EUR) From above. €144.03
Current discount Discount to share price of €83.32
= -1 x (€83.32 - €144.03) / €144.03
42.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Celgene is available for.
Intrinsic value
42%
Share price is €83.32 vs Future cash flow value of €144.03
Current Discount Checks
For Celgene to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Celgene's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Celgene's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Celgene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Celgene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CG3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $5.65
NasdaqGS:CELG Share Price ** NasdaqGS (2019-04-18) in USD $93.76
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Celgene.

DB:CG3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CELG Share Price ÷ EPS (both in USD)

= 93.76 ÷ 5.65

16.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celgene is good value based on earnings compared to the Europe Biotechs industry average.
  • Celgene is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Celgene's expected growth come at a high price?
Raw Data
DB:CG3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts
16.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:CG3 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.6x ÷ 16.1%

1.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celgene is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Celgene's assets?
Raw Data
DB:CG3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $8.80
NasdaqGS:CELG Share Price * NasdaqGS (2019-04-18) in USD $93.76
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:CG3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CELG Share Price ÷ Book Value per Share (both in USD)

= 93.76 ÷ 8.80

10.66x

* Primary Listing of Celgene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celgene is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Celgene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Celgene has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Celgene expected to perform in the next 1 to 3 years based on estimates from 21 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Celgene expected to grow at an attractive rate?
  • Celgene's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Celgene's earnings growth is expected to exceed the Germany market average.
  • Celgene's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CG3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CG3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 21 Analysts 16.1%
DB:CG3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 21 Analysts 8.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CG3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CG3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 22,582 10,920 9,911 12
2022-12-31 23,360 10,554 9,401 13
2021-12-31 21,768 9,797 8,517 16
2020-12-31 19,264 8,047 7,268 20
2019-12-31 17,097 7,588 6,165 21
DB:CG3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 15,281 5,171 4,046
2018-09-30 14,727 4,517 2,892
2018-06-30 14,122 3,681 2,798
2018-03-31 13,579 4,068 2,854
2017-12-31 13,003 5,246 2,940
2017-09-30 12,500 4,959 3,450
2017-06-30 12,196 4,641 2,633
2017-03-31 11,679 4,018 2,130
2016-12-31 11,229 4,165 1,999
2016-09-30 10,812 3,821 2,131
2016-06-30 10,163 3,336 1,926
2016-03-31 9,687 2,627 1,684

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Celgene's earnings are expected to grow by 16.1% yearly, however this is not considered high growth (20% yearly).
  • Celgene's revenue is expected to grow by 8.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CG3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below

All data from Celgene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CG3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 14.69 16.55 13.18 4.00
2022-12-31 13.49 15.08 11.44 5.00
2021-12-31 12.10 13.31 9.67 6.00
2020-12-31 9.93 11.19 7.30 9.00
2019-12-31 8.22 8.96 6.20 10.00
DB:CG3 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 5.65
2018-09-30 3.94
2018-06-30 3.70
2018-03-31 3.70
2017-12-31 3.77
2017-09-30 4.42
2017-06-30 3.38
2017-03-31 2.74
2016-12-31 2.57
2016-09-30 2.73
2016-06-30 2.46
2016-03-31 2.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Celgene is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Celgene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Celgene has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Celgene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Celgene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Celgene's year on year earnings growth rate has been positive over the past 5 years.
  • Celgene's 1-year earnings growth exceeds its 5-year average (37.6% vs 17.2%)
  • Celgene's earnings growth has exceeded the Europe Biotechs industry average in the past year (37.6% vs 18.2%).
Earnings and Revenue History
Celgene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Celgene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CG3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 15,281.00 4,046.00 3,154.00 5,101.00
2018-09-30 14,727.00 2,892.00 3,117.00 4,916.00
2018-06-30 14,122.00 2,798.00 3,036.00 4,583.00
2018-03-31 13,579.00 2,854.00 2,870.00 4,256.00
2017-12-31 13,003.00 2,940.00 2,626.00 3,274.00
2017-09-30 12,500.00 3,450.00 2,468.00 3,469.00
2017-06-30 12,196.00 2,633.00 2,528.00 4,041.00
2017-03-31 11,679.00 2,130.00 2,536.00 3,935.00
2016-12-31 11,229.00 1,999.00 2,459.00 3,543.00
2016-09-30 10,812.30 2,131.00 2,447.00 3,098.20
2016-06-30 10,163.40 1,925.90 2,329.30 2,324.00
2016-03-31 9,687.20 1,684.10 2,314.10 2,198.20
2015-12-31 9,256.00 1,602.00 2,300.00 2,089.00
2015-09-30 8,778.20 1,654.90 2,240.70 1,910.60
2015-06-30 8,426.30 2,197.50 2,188.00 1,961.70
2015-03-31 8,021.20 2,439.10 2,063.00 1,868.80
2014-12-31 7,670.40 1,999.90 2,027.90 1,796.30
2014-09-30 7,340.80 1,600.40 1,932.20 1,869.30
2014-06-30 7,033.00 1,464.40 1,883.30 1,695.60
2014-03-31 6,759.30 1,344.70 1,809.60 1,634.30
2013-12-31 6,493.90 1,449.90 1,684.50 1,580.10
2013-09-30 6,185.40 1,498.60 1,605.90 1,470.70
2013-06-30 5,930.20 1,550.30 1,511.80 1,392.60
2013-03-31 5,698.00 1,439.60 1,416.70 1,391.50
2012-12-31 5,506.70 1,456.20 1,373.50 1,417.60
2012-09-30 5,343.20 1,603.28 1,318.51 1,418.93
2012-06-30 5,173.73 1,552.06 1,267.21 1,285.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Celgene made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • Celgene used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Celgene has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Celgene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Celgene has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Celgene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Celgene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Celgene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Celgene's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Celgene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Celgene Company Filings, last reported 3 months ago.

DB:CG3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6,161.00 20,270.00 6,049.00
2018-09-30 4,860.00 20,290.00 4,387.00
2018-06-30 3,430.00 21,287.00 3,417.00
2018-03-31 5,172.00 20,271.00 4,747.00
2017-12-31 6,921.00 15,838.00 12,045.00
2017-09-30 9,850.00 14,281.00 11,787.00
2017-06-30 8,445.00 14,287.00 10,143.00
2017-03-31 7,644.00 14,286.00 8,862.00
2016-12-31 6,600.00 14,290.00 7,971.00
2016-09-30 5,650.30 14,303.50 6,868.60
2016-06-30 5,548.80 14,312.10 6,437.50
2016-03-31 5,074.80 14,268.30 5,729.30
2015-12-31 5,919.00 14,162.30 6,582.70
2015-09-30 5,375.50 15,497.60 7,529.20
2015-06-30 6,321.90 7,629.90 7,522.40
2015-03-31 6,764.80 6,818.60 7,334.50
2014-12-31 6,524.80 6,871.60 7,564.70
2014-09-30 5,768.40 6,864.80 6,876.50
2014-06-30 4,851.30 6,958.30 6,230.30
2014-03-31 4,484.60 5,145.50 5,124.70
2013-12-31 5,589.90 4,809.60 5,704.20
2013-09-30 5,894.70 4,679.00 5,858.70
2013-06-30 5,407.10 3,666.00 4,085.20
2013-03-31 5,554.40 3,133.00 3,524.90
2012-12-31 5,694.50 3,094.80 3,901.00
2012-09-30 5,728.71 3,094.21 3,833.09
2012-06-30 5,958.03 1,662.55 2,561.54
  • Celgene's level of debt (329%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (86.3% vs 329% today).
  • Debt is well covered by operating cash flow (25.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 7.9x coverage).
X
Financial health checks
We assess Celgene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Celgene has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Celgene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Celgene dividends. Estimated to be 0% next year.
If you bought €2,000 of Celgene shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Celgene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Celgene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CG3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 21 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CG3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Celgene has not reported any payouts.
  • Unable to verify if Celgene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Celgene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Celgene has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Celgene's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Celgene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Celgene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Celgene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Celgene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Alles
COMPENSATION $16,223,923
AGE 59
TENURE AS CEO 3.1 years
CEO Bio

Mr. Mark J. Alles has been the Chief Executive Officer of Celgene Corporation since March 1, 2016 and its chairman of the board since February 5, 2018. Mr. Alles served as the President and Chief Operating Officer of Celgene Corporation (also know as Celgene Inc.) and Celgene Limited from August 1, 2014 to March 1, 2016. He served as an Executive Vice President of Celgene Corporation since February 15, 2012 until August 1, 2014 and also served as its Global Head of Hematology & Oncology since December 2012 until August 1, 2014. He served as the Chief Commercial Officer at Celgene Corporation from February 15, 2012 to July 2014. He joined Celgene in April 2004 and served as Vice President of Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Prior to joining Celgene, Mr. Alles served as Vice President for the US Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11 year period with Aventis. He serving as a Captain in the United States Marine Corps, he started his 25-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He has been a Director of Celgene Corporation since February 11, 2016. He serves as a Director for Gilda’s Club NYC, a not-for-profit organization helping people with cancer. He serves as a Trustee of The Healthcare Institute of New Jersey. Mr. Alles served as an Observer of Acetylon Pharmaceuticals, Inc., since February 9, 2012. Mr. Alles has B.S. degree from Lock Haven University of Pennsylvania.

CEO Compensation
  • Mark's compensation has increased by more than 20% in the past year.
  • Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Celgene management team in years:

0.7
Average Tenure
53.5
Average Age
  • The average tenure for the Celgene management team is less than 2 years, this suggests a new team.
Management Team

Mark Alles

TITLE
Chairman & CEO
COMPENSATION
$16M
AGE
59
TENURE
3.1 yrs

David Elkins

TITLE
Executive VP & CFO
COMPENSATION
$13M
AGE
49
TENURE
0.7 yrs

Peter Kellogg

TITLE
Executive VP & Chief Corporate Strategy Officer
COMPENSATION
$6M
AGE
62
TENURE
0.7 yrs

S. J. Vessey

TITLE
President of Research & Early Development
COMPENSATION
$6M
AGE
53
TENURE
3.3 yrs

Alise Reicin

TITLE
President of Global Clinical Development
COMPENSATION
$6M
AGE
57
TENURE
0.4 yrs

Terrie Curran

TITLE
President of Global Inflammation & Immunology
COMPENSATION
$4M
AGE
49
TENURE
2 yrs

Jazz Tobaccowalla

TITLE
Senior VP and Chief Digital & Information Officer
AGE
51
TENURE
0.7 yrs

Patrick Flanigan

TITLE
Corporate Vice President of Investor Relations

Jonathan Biller

TITLE
Executive VP & General Counsel
AGE
54
TENURE
0.8 yrs

Toni-Ann Citera

TITLE
Senior VP & Chief Compliance Officer
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Celgene board of directors in years:

7.7
Average Tenure
66
Average Age
  • The tenure for the Celgene board of directors is about average.
Board of Directors

Mark Alles

TITLE
Chairman & CEO
COMPENSATION
$16M
AGE
59
TENURE
1.2 yrs

Mike Casey

TITLE
Independent Lead Director
COMPENSATION
$590K
AGE
72
TENURE
11.8 yrs

James Loughlin

TITLE
Independent Director
COMPENSATION
$565K
AGE
75
TENURE
12.3 yrs

Ernie Mario

TITLE
Independent Director
COMPENSATION
$560K
AGE
79
TENURE
11.7 yrs

Carrie Cox

TITLE
Independent Director
COMPENSATION
$536K
AGE
60
TENURE
9.3 yrs

Michael Friedman

TITLE
Independent Director
COMPENSATION
$530K
AGE
74
TENURE
8.2 yrs

Richard Barker

TITLE
Independent Director
COMPENSATION
$538K
AGE
69
TENURE
7.3 yrs

Mike Bonney

TITLE
Independent Director
COMPENSATION
$536K
AGE
60
TENURE
4 yrs

Julia Haller

TITLE
Independent Director
COMPENSATION
$538K
AGE
63
TENURE
3.5 yrs

John Weiland

TITLE
Independent Director
COMPENSATION
$822K
AGE
62
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Celgene insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Feb 19 Buy Ernest Mario Individual 12. Feb 19 12. Feb 19 2,000 €79.52 €159,048
13. Aug 18 Sell Ernest Mario Individual 09. Aug 18 09. Aug 18 -12,000 €79.79 €-957,437
07. Aug 18 Buy John Weiland Individual 07. Aug 18 07. Aug 18 5,575 €77.42 €431,616
17. May 18 Buy Mark Alles Individual 09. May 18 09. May 18 1,208 €69.66 €84,148
X
Management checks
We assess Celgene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Celgene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Details
Name: Celgene Corporation
CG3
Exchange: DB
Founded: 1980
$58,564,271,327
702,450,444
Website: http://www.celgene.com
Address: Celgene Corporation
86 Morris Avenue,
Summit,
New Jersey, 07901,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CELG Common Stock Nasdaq Global Select US USD 28. Jul 1987
DB CG3 Common Stock Deutsche Boerse AG DE EUR 28. Jul 1987
XTRA CG3 Common Stock XETRA Trading Platform DE EUR 28. Jul 1987
LSE 0QYA Common Stock London Stock Exchange GB USD 28. Jul 1987
SWX CELG Common Stock SIX Swiss Exchange CH CHF 28. Jul 1987
WBAG CELG Common Stock Wiener Boerse AG AT EUR 28. Jul 1987
BMV CELG * Common Stock Bolsa Mexicana de Valores MX MXN 28. Jul 1987
BASE CELG CEDEAR EACH 5 REP 1 COM USD0.01 Buenos Aires Stock Exchange AR ARS 12. Apr 2019
BOVESPA CLGN34 EACH BDR REPR 1 COM USD0.01 Bolsa de Valores de Sao Paulo BR BRL 23. Nov 2015
Number of employees
Current staff
Staff numbers
8,852
Celgene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:47
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.